Last reviewed · How we verify
INF2.0 + IBU
INF2.0 + IBU is a combination of interferon alpha-2b (INF2.0) and ibuprofen (IBU) that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic properties.
INF2.0 + IBU is a combination of interferon alpha-2b (INF2.0) and ibuprofen (IBU) that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic properties. Used for Unknown — marketed status at St. Justine's Hospital (pediatric center) suggests possible viral infection or immunological indication, but specific approved indication is not documented in standard references.
At a glance
| Generic name | INF2.0 + IBU |
|---|---|
| Sponsor | St. Justine's Hospital |
| Drug class | Combination therapy (interferon + NSAID) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Virology |
| Phase | FDA-approved |
Mechanism of action
Interferon alpha-2b is a cytokine that enhances immune responses and has antiviral activity, while ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis. The combination aims to leverage both immunomodulation and symptomatic relief, though the clinical rationale for this specific pairing is not well-established in standard literature.
Approved indications
- Unknown — marketed status at St. Justine's Hospital (pediatric center) suggests possible viral infection or immunological indication, but specific approved indication is not documented in standard references
Common side effects
- Flu-like symptoms (from interferon)
- Gastrointestinal upset (from ibuprofen)
- Headache
- Fever
Key clinical trials
- A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INF2.0 + IBU CI brief — competitive landscape report
- INF2.0 + IBU updates RSS · CI watch RSS
- St. Justine's Hospital portfolio CI